A Study of Daratumumab in Patients With Relapsed or Refractory Waldenström Macroglobulinemia


Original post, click here

Condition:   Waldenström Macroglobulinemia
Intervention:   Drug: Daratumumab
Sponsors:   Dana-Farber Cancer Institute;   Janssen, LP
Not yet recruiting – verified June 2017